NC 2500

Drug Profile

NC 2500

Alternative Names: NC-2500

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Chemiphar
  • Class Antigouts
  • Mechanism of Action Xanthine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hyperuricaemia

Highest Development Phases

  • Phase I Hyperuricaemia

Most Recent Events

  • 13 Jun 2018 NC 2500 is still in phase I trials for Hyperuricemia(PO) in Japan
  • 13 Jun 2018 Efficacy and pharmacokinetics data from a phase I trial in Hyperuricaemia presented at the at 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 30 Nov 2017 Nippon completes a phase I trial in Hyperuricemia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top